ПРИМЕНЕНИЕ НОВОГО АНТИЭПИЛЕПТИЧЕСКОГО ПРЕПАРАТА — ЗОНЕГРАН (ЗОНИСАМИД) — В ЛЕЧЕНИИ ЭПИЛЕПСИИ (ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
Несмотря на значительные успехи, достигнутые в эпилептологии, резистентные эпилепсии составляют примерно 30% среди всех форм эпилепсии. Представлен обзор современной литературы, посвященный эффективности и безопасности нового антиэпилептического препарата зонегран (зонисамид) в лечении эпилепсии. Рассмотрен механизм действия, особенности фармакокинетики, эффективность и переносимость зонисамида при резистентной фокальной эпилепсии, а также при других типах приступов и формах эпилепсии. Рассматриваются возможности применения зонисамида при коморбидных состояниях.
Ключевые слова
Об авторах
О. А. Пылаева
Институт детской неврологии и эпилепсии имени Святителя Луки, Москва
Россия
Россия
К. Ю. Мухин
Институт детской неврологии и эпилепсии имени Святителя Луки, Москва
Россия
Россия
Список литературы
1. Abdoh M., Mersfelder T.L., Melgar T.A. Psychosis Induced by Zonisamide: a Case Report and Review of the Literature // Am J Ther. — 2011 Oct 17. [Epub ahead of print].
2. Akman C.I., Goodkin H.P., Rogers D.P., Riviello J.J.Jr. Visual hallucinations associated with zonisamide // Pharmacotherapy. — 2003. — V. 23(1). — P. 93-6.
3. Arzimanoglou A., Rahbani A. Zonisamide for the treatment of epilepsy // Expert Rev Neurother. — 2006. — V. 6(9). — P. 1283-92.
4. Baulac M. Introduction to zonisamide // Epilepsy Res. — 2006. — V. 68 (Suppl 2). — P. 3-9.
5. Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures // Epilepsy Res. — 2007. — V. 75(2-3). — P. 75-83. Epub 2007 Jun 5.
6. Bermejo P.E., Anciones B. A review of the use of zonisamide in Parkinson's disease // Ther Adv Neurol Disord. — 2009. — V. 2(5). — P. 313-7.
7. Bernstein C.D., Diaz J.H., Gould H.J. 3rd. A possible role for zonisamide in treating neuropathic pain: a case of idiopathic polyneuropathy // Pain Pract. — 2002. — V. 2(2). — P. 134-6.
8. Biton V. Clinical pharmacology and mechanism of action of zonisamide // Clin Neuropharmacol. — 2007. — V. 30(4). — P. 230-40.
9. Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action // Expert Rev Neurother. — 2004. — V. 4(6). — P. 935-43.
10. Bos M., Bauer J. Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients // Nervenarzt. 2007 Dec;78(12):1425-9.
11. Brodie M.J. Zonisamide as adjunctive therapy for refractory partial seizures // Epilepsy Res. — 2006. — V. 68 Suppl 2. — P. 11-6. Epub 2005 Nov 28.
12. Brodie M.J. Zonisamide clinical trials: European experience // Seizure. — 2004. — V. 13 (Suppl 1). — P. 66-70; discussion P. 71-2.
13. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitenskyy V., Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures // Epilepsia. — 2005. — V. 46(1). — P. 31-41.
14. Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy // Cochrane Database Syst Rev. — 2002;(2):CD001416.
15. Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy // Cochrane Database Syst Rev. — 2005. — V. 19;(4):CD001416
16. Cohen A.F., van Bronswijk H. New medications; zonisamide // Ned Tijdschr Geneeskd. — 2006. — V. 150(42). — P. 2313.
17. Coppola G., Grosso S., Verrotti A., Parisi P. Luchetti A., Franzoni E., Mangano S., Pelliccia A., Operto F.F., Iannetti P., Curatolo P., Balestri P., Pascotto A. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study // Epilepsy Res. — 2009. — V. 83(2-3). — P. 112-6. Epub 2008 Dec 10.
18. Crawford P.M. Managing epilepsy in women of childbearing age // Drug Saf. — 2009. — V. 32(4). — P. 293-307.
19. DiMauro S., Hirano M. MERRF / In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K., ed. / GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2003 Jun 03 [updated 2009 Aug 18].
20. Dupont S., Striano S., Trinka E., Springub J., Giallonardo A.T., Smith P., Ellis S., Yeates A., Baker G. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, openlabel study (ZEUS) // Acta Neurol Scand. — 2010. — V. 121(3). — P. 141-8.
21. Elger C.E., Schmidt D. Modern management of epilepsy: A practical approach // Epilepsy & Behavior. — 2008. — V. 12. — P. 501–539.
22. Farooq M.U., Moore P.W., Bhatt A., Aburashed R., Kassab M.Y. Therapeutic role of zonisamide in neuropsychiatric disorders // Mini Rev Med Chem. — 2008. — V. 8(10). — P. 968-75.
23. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures // Seizure. — 2004. — V. 13 (Suppl 1). — P. 59-65; discussion P. 71-2.
24. Fox M.H., Bassuk A.G. Progressive Myoclonus Epilepsy with Ataxia / In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K., ed. / GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2009 Sep 08.
25. Frampton J.E., Scott L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy // CNS Drugs. — 2005. — V. 19(4). — P. 347-67.
26. Fujita Y., Hasegawa M., Nabeshima K., Tomita M., Murakami K., Nakai S., Yamakita T., Matsunaga K. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome // Intern Med. — 2010. — V. 49(5). — P. 409-13. Epub 2010 Mar 1.
27. Fukuoka N., Tsukamoto T., Uno J., Kimura M., Morita S. Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: quantitative analysis based on suitable transforming factor // Biol Pharm Bull. — 2003. — V. 26(12). — 1734-8.
28. Fukushima K., Seino M. A long-term follow-up of zonisamide monotherapy // Epilepsia. — 2006. — V. 47(11). — P. 1860-4.
29. Gadde K.M., Franciscy D.M., Wagner H.R. 2nd, Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial // JAMA. — 2003. — V. 289(14). — P. 1820-5.
30. Helmstaedter C., Stefan H,. Witt J.A. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study // Epileptic Disord. —2011. — V. 13(3). — P. 263-76.
31. Hirai K., Kimiya S., Tabata K., Seki T., Jozaki K., Kumagai N. Selective mutism and obsessive compulsive disorders associated with zonisamide // Seizure. — 2002. — V. 11(7). — P. 468-70.
32. Hirose M., Yokoyama H., Haginoya K., Iinuma K. A five-year-old girl with epilepsy showing forced normalization due to zonisamide // No To Hattatsu. — 2003. — V. 35(3). — P. 259-63.
33. Hirose S., Kurahashi H. Autosomal Dominant Nocturnal Frontal Lobe Epilepsy / In: Pagon R.A., Bird T.D., Dolan C.R., Stephens K., ed. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2002 May 16 [updated 2010 Apr 05].
34. Holder J.L. Jr., Wilfong A.A. Zonisamide in the treatment of epilepsy // Expert Opin Pharmacother. — 2011. —V. 12(16). — P. 2573-81.
35. Iinuma K., Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey // Seizure. — 2004. — V. 13 (Suppl 1). — P. 34-9; discussion S40
36. Italiano D., Pezzella M., Coppola A., Magaudda A., Ferlazzo E., Bramanti P., Striano S., Zara F., Striano P. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease // Mov Disord. — 2011. — V. 26(2). —P. 341-3.
37. Janszky J. Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases //Ideggyogy Sz. — 2009. — V. 30;62(11-12). — P. 383-9.
38. Joo E.Y., Kim H.J., Lim Y.H., Ji K.H., Hong S.B. Zonisamide changes unilateral cortical excitability in focal epilepsy patients // J Clin Neurol. — 2010. — V. 6(4). — P. 189-95. Epub 2010 Dec 31.
39. Joo E.Y., Kim S.H., Seo D.W., Hong S.B. Zonisamide decreases cortical excitability in patients with idiopathic generalized epilepsy // Clin Neurophysiol. — 2008. — V. 119(6). — P. 1385-92.
40. Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center // J Child Neurol. — 2005. — V. 20(3). — P. 212-9.
41. Kelemen A., Rasonyl G., Neuwirth M., Barcs G., Szucs A., Jakus R., Fabo D., Juhos V., Palfy B, Halasz P. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes // Ideggyogy Sz. — 2011. — V. 64(5-6). — P. 187-92.
42. Kelley S.A., Kossoff E.H. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress // Dev Med Child Neurol. — 2010. — 52(11). — P. 988-93.
43. Kluger G., Zsoter A., Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy // Eur J Paediatr Neurol. — 2008. — V. 12(1). — P. 19-23. Epub 2007 Jun 18.
44. Kothare S.V., Kaleyias J., Mostofi N., Valencia I., Melvin J.J., Hobdell E., Khurana D.S., Legido A. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy // Pediatr Neurol. — 2006. — V. 34(5). — P. 351-4.
45. Kothare S.V., Valencia I., Khurana D.S., Hardison H., Melvin J.J., Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy // Epileptic Disord. — 2004. — V. 6(4). — P. 267-70.
46. Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety // Expert Opin Drug Metab Toxicol. — 2008. — V. 4(4). — P. 493-506.
47. Kwak S.E., Kim J.E., Kim D.S., Won M.H., Choi H.C., Kim Y.I., Song H.K., Choi S.Y., Kang T.C. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil // Neuropeptides. — 2005. — V. 39(5). — P. 507-13. Epub 2005 Sep 27.
48. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions // Expert Rev Neurother. — 2006. — V. 6(3). — P. 397–406.
49. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? // Seizure. — 2000. — V. 9 (7). —P. 464–8.
50. Kwan P., Brodie M.J. Early identification of refractory epilepsy // N Engl J Med. — 2000. — V. 342(5). — P. 314–9.
51. Lee Y.J., Kang H.C., Seo J.H., Lee J.S., Kim H.D. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy // Brain Dev. — 2010. — V. 32(3). — P. 208-12. Epub 2009 Mar 21.
52. Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics // Seizure. — 2004. — V. 13 (Suppl 1). — P. 5-9; discussion P10.
53. Leppik I.E. Practical prescribing and long-term efficacy and safety of zonisamide // Epilepsy Res. — 2006. —V. 68 Suppl 2:S17-24. Epub 2006 Jan 9.
54. Lim J., Ko Y.H., Joe S.H., Han C., Lee M.S., Yang J. Zonisamide produces weight loss in psychotropic drugtreated psychiatric outpatients // Prog Neuropsychopharmacol Biol Psychiatry. — 2011. — V. 35(8). — P. 1918-21. Epub 2011 Jul 22.
55. Lopez-Trigo J., Ortiz-Sanchez P., Blanco-Hernandez T. Zonisamide and neuropathic pain // Rev Neurol. — 2007. — V. 45(7). — P. 429-32.
56. Lotze T.E., Wilfong A.A. Zonisamide treatment for symptomatic infantile spasms // Neurology. — 2004. — V. 62(2). — P. 296-8.
57. Lu Y., Xiao Z., Yu W., Xiao F., Xiao Z., Hu Y., Chen Y., Wang X. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial // Clin Drug Investig. — 2011. — V. 31(4). — P. 221-9.
58. Marazziti D., Rossi L., Baroni S., Consoli G., Hollander E., Catena-Dell'osso M. Novel Treatment Options of Binge Eating Disorder // Curr Med Chem. — 2011 Oct 26. [Epub ahead of print]
59. Mares P. Zonisamide suppresses the tonic phase but not the clonic phase of generalized seizures in developing rats // Epilepsy Res. — 2010. — V. 92(2-3). — P. 244-8.
60. Marinas A., Villanueva V., Giraldez BG., Molins A., Salas-Puig J., Serratosa J.M. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy // Epileptic Disord. — 2009. — V. 11(1). — P. 61-6. Epub 2009 Mar 5.
61. Marmarou A., Pellock J.M. Zonisamide: physician and patient experiences // Epilepsy Res. — 2005. — V. 64(1-2). — P. 63-9.
62. Mirza N.S., Alfirevic A., Jorgensen A., Marson A.G., Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors // Pharmacogenet Genomics. — 2011. — V. 21(5). — P. 297-302.
63. Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies // Seizure. — 2004. — V. 13 (Suppl 1). — P. 17-23; discussion S24-5.
64. Miwa H. Zonisamide for the treatment of Parkinson's disease // Expert Rev Neurother. — 2007. — V. 7(9). —P. 1077-83.
65. Mohammadianinejad S.E., Abbasi V., Sajedi S.A., Majdinasab N., Abdollahi F., Hajmanouchehri R., Faraji A. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial // Clin Neuropharmacol. — 2011. — V. 34(4). — P. 174-7.
66. Montouris G., Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? // Epilepsia. — 2009. — V. 50 Suppl 8. — P. 16-20.
67. Murata M. The discovery of an antiparkinsonian drug, zonisamide // Rinsho Shinkeigaku. — 2010. — V. 50(11). — P. 780-2.
68. Ohtahara S. Zonisamide in the management of epilepsy– Japanese experience // Epilepsy Res. — 2006. — V. 68. — Suppl 2. — P. 25-33.
69. Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey // Seizure. — 2004. — V. 13 (Suppl 1). — P. 50-5; discussion P. 56.
70. Oles K.S., Bell W.L. Zonisamide concentrations during pregnancy // Ann Pharmacother. — 2008. — V. 42(7). — P. 1139-41. Epub 2008 Jun 24.
71. O'Rourke D., Flynn C., White M., Doherty C., Delanty N. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series // Ir Med J. —2007. — V. 100(4). — P. 431-3.
72. Park S.P., Hwang Y.H., Lee H.W., Suh C.K., Kwon S.H., Lee B.I Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients // Epilepsy Behav. — 2008. — V. 12(1). — P. 102-8. Epub 2007 Oct 22.
73. Park S.P., Kim S.Y., Hwang Y.H., Lee H.W., Suh C.K., Kwon S.H. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients // J Clin Neurol. — 2007. — V. 3(4). — P. 175-80. Epub 2007 Dec 20.
74. Ragueneau-Majlessi I., Levy R.H., Bergen D., Garnett W., Rosenfeld W., Mather G., Shah J., Grundy J.S. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients // Epilepsy Res. — 2004. — V. 62(1). — P. 1-11.
75. Russo E., Citraro R., Scicchitano F., De Fazio S., Perrota I., Di Paola E.D., Constanti A., De Sarro G. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model // Epilepsia. — 2011. — V. 52(7). — P. 1341-50.
76. Sackellares J.C., Ramsay R.E., Wilder B.J., Browne T.R. 3rd., Shellenberger M.K. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures // Epilepsia. — 2004. — V. 45(6). — P. 610-7.
77. Santos C.C., Brotherton T. Use of zonisamide in pediatric patients // Pediatr Neurol. — 2005. — V. 33(1). — P. 12-4.
78. Seino M. Review of zonisamide development in Japan // Seizure. — 2004. — V. 13 (Suppl 1). — P. 2-4.
79. Seki T., Kumagai N., Maezawa M. Effects of zonisamide monotherapy in children with epilepsy // Seizure. — 2004. — V. 13. — Suppl 1. — P. 26-32; discussion P. 33.
80. Sills G., Brodie M. Pharmacokinetics and drug interactions with zonisamide // Epilepsia. — 2007. — V. 48(3). — P. 435-41.
81. Schulze-Bonhage A. Zonisamide in the treatment of epilepsy // Expert Opin Pharmacother. — 2010. — V. 11(1). — P. 115-26.
82. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z., Malek R., Piskorska B., Czuczwar S.J. Zonisamide: a new antiepileptic drug // Pol J Pharmacol. — 2003. — V. 55(5). — P. 683-9.
83. Suzuki Y., Imai K., Toribe Y., Ueda H., Yanagihara K., Shimono K., Okinaga T., Ono J., Nagai T., Matsuoka T., Tagawa T., Abe J., Morita Y., Fujikawa Y., Arai H., Mano T., Okada S. Long-term response to zonisamide in patients with West syndrome // Neurology. — 2002. — V. 58(10). — P. 1556-9.
84. Szaflarski J.P. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy // Epilepsy Behav. — 2004. — V. 5(6). — P. 1024-6.
85. Takahashi S., Ohinata J., Suzuki N., Amamiya S., Kajihama A., Sugai R., Araki A., Fujieda K., Tanaka H. Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures // Epilepsy Res. — 2008. — V. 80(1). — P. 18-22
86. Tan H.J., Martland T.R., Appleton R.E., Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review // Seizure. — 2010. — V. 19(1). — P. 31-5.
87. Thone J., Leniger T., Splettstosser F., Wiemann M. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition // Epilepsy Res. — 2008. — V. 79(2-3). — P. 105-11.
88. Tosches W.A., Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide // Epilepsy Behav. — 2006. — V. 8(3). — P. 522-6.
89. Tsao C.Y. Current trends in the treatment of infantile spasms // Neuropsychiatr Dis Treat. — 2009. — V. 5. — P. 289-99.
90. Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures // Brain Res Mol Brain Res. — 2003. — V. 116(1-2). — P. 1-6.
91. Uthman B.M., Miller G.S., Montouris G., James S.P., Anthony S.; Zonisamide 501 Study Group. Safety of 25-and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study // Curr Med Res Opin. — 2004. — V. 20(6). — P. 837-42.
92. Vossler D.G., Conry J.A., Murphy J.V.; ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study // Epileptic Disord. — 2008. — V. 10(1). — P. 31-4.
93. Wellmer J., Wellmer S., Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy // Acta Neurol Scand. — 2009. — V. 119(4). — P. 233-8.
94. Wellmer S., Wellmer J., Bauer J. Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients // Nervenarzt. — 2008. — V. 79(12). — P. 1416, 1418-23.
95. White J.R., Walczak T.S., Marino S.E., Beniak T.E., Leppik I.E., Birnbaum A.K. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study // Neurology. — 2010. — V. 75(6). — P. 513-8.
96. Wilfong A., Schultz R. Zonisamide for absence seizures // Epilepsy Res. — 2005. — V. 64(1-2). — P. 31-4. Epub 2005 Apr 19.
97. Wilfong A.A. Zonisamide monotherapy for epilepsy in children and young adults // Pediatr Neurol. — 2005. — V. 32(2). — P. 77-80.
98. Wilfong A.A., Willmore L.J. Zonisamide - a review of experience and use in partial seizures // Neuropsychiatr Dis Treat. — 2006. — V. 2(3). — P. 269-80.
99. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? // Curr Med Res Opin. — 2007. — V. 23(8). — P. 1765-73.
100. Wroe S.J., Yeates A.B., Marshall A. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy // Acta Neurol Scand. — 2008. — V. 118(2). — P. 87-93. Epub 2008 Jun 10.
101. Yamamura S., Ohoyama K., Nagase H., Okada M. Zonisamide enhances delta receptor-associated neuro-transmitter release in striato-pallidal pathway // Neuropharmacology. — 2009. — V. 57(3). — P. 322-31.
102. Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience // Seizure. — 2004. — V. 13 (Suppl 1). — P. 41-8; discussion P. 49.
103. Yanagaki S., Oguni H., Yoshii K., Hayashi K., Imai K., Funatsuka M., Osawa M. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate // Brain Dev. — 2005. — V. 27(4). — P. 286-90.
104. You S.J., Kang H.C., Kim H.D., Lee H.S., Ko T.S. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience // Brain Dev. — 2008. — V. 30(4). — P. 287-90. Epub 2007 Oct 23.
105. Yum M.S., Ko T.S. Zonisamide in West syndrome: an open label study // Epileptic Disord. — 2009. — V. 11(4). — P. 339-44. Epub 2010 Jan 4.
106. Zaccara G., Specchio L.M. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature // Neuropsychiatr Dis Treat. — 2009. — V. 5. — P. 249-59. Epub 2009 May 20.
107. Zaccara G., Tramacere L., Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy // Expert Opin Drug Saf. — 2011. — V. 10(4). — P. 623-31.
108. Zareba G. Zonisamide: review of its use in epilepsy therapy // Drugs Today (Barc). — 2005. — V. 41(9). — P. 589-97.
109. Zesiewicz T.A., Elble R.J., Louis E.D., Gronseth G.S., Ondo W.G., Dewey R.B.Jr., Okun M.S., Sullivan K.L., Weiner W.J. Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology // Neurology. — 2011. — V. 77(19). — P. 1752-5. Epub 2011 Oct 19.
110. Zesiewicz T.A., Ward C.L., Hauser R.A., Sanchez-Ramos J., Staffetti J.F., Sullivan K.L. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor // Mov Disord. — 2007. — V. 22(2). — P. 279-82.
Для цитирования:
Пылаева О.А., Мухин К.Ю. ПРИМЕНЕНИЕ НОВОГО АНТИЭПИЛЕПТИЧЕСКОГО ПРЕПАРАТА — ЗОНЕГРАН (ЗОНИСАМИД) — В ЛЕЧЕНИИ ЭПИЛЕПСИИ (ОБЗОР ЛИТЕРАТУРЫ). Русский журнал детской неврологии. 2012;7(2):13-34. https://doi.org/10.17650/2073-8803-2012-7-2-13-34
For citation:
Pylaeva O.A., Мukhin K.Y. A NEW ANTIEPILEPTIC DRUG — ZONEGRAN (ZONISAMIDE) — IN THE TREATMENT OF EPILEPSY (A REVIEW). Russian Journal of Child Neurology. 2012;7(2):13-34. (In Russ.) https://doi.org/10.17650/2073-8803-2012-7-2-13-34
Просмотров: 345
Послать статью по эл. почте 